Intravenous use of amrinone for the treatment of the failing heart.

[1]  D. B. Evans,et al.  Studies aimed at elucidating the mechanism of action of CI-914, a new cardiotonic agent. , 1985, European journal of pharmacology.

[2]  M. Packer,et al.  Hemodynamic and clinical limitations of long-term inotropic therapy with amrinone in patients with severe chronic heart failure. , 1984, Circulation.

[3]  A. Katz,et al.  Inotropic drugs and their mechanisms of action. , 1984, Journal of the American College of Cardiology.

[4]  R. Kauffman,et al.  Molecular basis for the cardiovascular activities of amrinone and AR-L57. , 1984, The Journal of pharmacology and experimental therapeutics.

[5]  E. Sonnenblick,et al.  Should the failing heart be stimulated? , 1984, The New England journal of medicine.

[6]  J. Ansell,et al.  Amrinone-induced thrombocytopenia. , 1984, Archives of internal medicine.

[7]  R. N. Brogden,et al.  Amrinone. A preliminary review of its pharmacological properties and therapeutic use. , 1983, Drugs.

[8]  M. Webb-Peploe,et al.  Side effects of amrinone therapy. , 1983, British heart journal.

[9]  P. Poole‐Wilson,et al.  Acute haemodynamic comparison of amrinone and pirbuterol in chronic heart failure. Additional effects of isosorbide dinitrate. , 1983, British heart journal.

[10]  C. Fry,et al.  The Inotropic and Vasodilator Properties of Amrinone on Isolated Human Tissue , 1983 .

[11]  D. Coltart,et al.  Haemodynamic effects of intravenous amrinone in patients with impaired left ventricular function. , 1983, British heart journal.

[12]  H. R. Kaplan,et al.  The effect of several “new and novel” cardiotonic agents on key subcellular processes involved in the regulation of myocardial contractility: Implications for mechanism of action , 1983 .

[13]  G. Hervey,et al.  Luxuskonsumption, diet-induced thermogenesis and brown fat: a critical review. , 1983, Clinical science.

[14]  C. O. Lee,et al.  Effect of strophanthidin on intracellular Na ion activity and twitch tension of constantly driven canine cardiac Purkinje fibers. , 1982, Biophysical journal.

[15]  N. Taira,et al.  Positive inotropic effect of amrinone in relation to cyclic nucleotide metabolism in the canine ventricular muscle. , 1982, The Journal of pharmacology and experimental therapeutics.

[16]  R. C. Dage,et al.  Biochemical Studies on the Mechanism of Cardiotonic Activity of MDL 17,043 , 1982, Journal of cardiovascular pharmacology.

[17]  E. Sonnenblick,et al.  Long-term amrinone therapy in patients with severe heart failure: drug-dependent hemodynamic benefits despite progression of disease. , 1982, The American journal of medicine.

[18]  J. White,et al.  Acute effects of amrinone on regional myocardial and systemic blood flow distribution in the dog. , 1982, Canadian journal of physiology and pharmacology.

[19]  E. Sonnenblick,et al.  Beneficial effect of amrinone on myocardial oxygen consumption during acute left ventricular failure in dogs. , 1981, The American journal of cardiology.

[20]  E. Sonnenblick,et al.  Hemodynamic comparison of intravenous amrinone and dobutamine in patients with chronic congestive heart failure. , 1981, The American journal of cardiology.

[21]  A. Fishman,et al.  Amrinone and exercise performance in patients with chronic heart failure. , 1981, The American journal of cardiology.

[22]  E. Sonnenblick,et al.  Relationship between amrinone plasma concentration and cardiac index , 1981, Clinical pharmacology and therapeutics.

[23]  E. Sonnenblick,et al.  Beneficial Effects of Amrinone‐Hydralazine Combination on Resting Hemodynamics and Exercise Capacity in Patients with Severe Congestive Heart Failure , 1981, Circulation.

[24]  J. Satriano,et al.  The effects of amrinone on transport and cyclic AMP metabolism in toad urinary bladder. , 1981, The Journal of pharmacology and experimental therapeutics.

[25]  J. Parker,et al.  Effects of amrinone, a cardiotonic drug, on calcium movements in dog erythrocytes. , 1980, The Journal of clinical investigation.

[26]  E. Braunwald,et al.  Effects of amrinone on experimental acute myocardial ischaemic injury. , 1980, Cardiovascular research.

[27]  E. Braunwald,et al.  Effects of Amrinone on Myocardial Energy Metabolism and Hemodynamics in Patients with Severe Congestive Heart Failure Due to Coronary Artery Disease , 1980, Circulation.

[28]  E. Braunwald,et al.  Oral amrinone in refractory congestive heart failure. , 1980, The American journal of cardiology.

[29]  E. Braunwald,et al.  Inotropic effect of amrinone in severe congestive heart failure: Lack of attenuation with sequential doses , 1980 .

[30]  C. van Breemen,et al.  The effects of amrinone on contractility, Ca2+ uptake and cAMP in smooth muscle. , 1980, European journal of pharmacology.

[31]  E. Sonnenblick,et al.  Sustained beneficial effects of oral amrinone on cardiac and renal function in patients with severe congestive heart failure. , 1980, The American journal of cardiology.

[32]  G. Y. Lesher,et al.  Cardiotonic Activity of Amrinone–Win 40680 [5‐Amino‐3,4f‐bipyridin‐6(lH)‐one] , 1979, Circulation research.

[33]  E. Sonnenblick,et al.  Amrinone A New Non-Glycosidic, Non-Adrenergic Cardiotonic Agent Effective in the Treatment of Intractable Myocardial Failure in Man , 1979, Circulation.

[34]  D. Severson,et al.  Cyclic nucleotides and cardiac function. , 1979, Circulation research.

[35]  E. Sonnenblick,et al.  Hemodynamic effects of intravenous and oral amrinone in patients with severe heart failure: relationship between intravenous and oral administration. , 1979, Transactions of the Association of American Physicians.

[36]  P. Epstein,et al.  Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. , 1979, Advances in cyclic nucleotide research.

[37]  E. Braunwald,et al.  Hemodynamic assessment of amrinone. A new inotropic agent. , 1978, The New England journal of medicine.

[38]  E. Sonnenblick,et al.  Mechanisms of beneficial effects of vasodilators and inotropic stimulation in the experimental failing ischemic heart. , 1978, The American journal of medicine.

[39]  S Ebashi,et al.  Excitation-contraction coupling. , 1976, Annual review of physiology.

[40]  E. Sonnenblick,et al.  Detection of latent function in acutely ischemic myocardium in the dog: comparison of pharmacologic inotropic stimulation and postextrasystolic potentiation. , 1975, Circulation research.

[41]  Appleman Mm,et al.  Regulation of cyclic nucleotide phosphodiesterase. , 1975, Advances in cyclic nucleotide research.

[42]  M. Samir Amer,et al.  Cyclic nucleotide phosphodiesterases: properties, activators, inhibitors, structure--activity relationships, and possible role in drug development. , 1975, Journal of pharmaceutical sciences.

[43]  J. Ross,et al.  Contractile performance of the hypertrophied and chronically failing cat ventricle. , 1972, The American journal of physiology.

[44]  D T Mason,et al.  Usefulness and limitations of the rate of rise of intraventricular pressure (dp-dt) in the evaluation of myocardial contractility in man. , 1969, The American journal of cardiology.

[45]  J. Ross,et al.  Oxygen consumption of the heart. Newer concepts of its multifactoral determination. , 1968, The American journal of cardiology.

[46]  J. Ross,et al.  Control of myocardial oxygen consumption: relative influence of contractile state and tension development. , 1968, The Journal of clinical investigation.

[47]  J. P. Gilmore,et al.  Inotropic augmentation of myocardial oxygen consumption. , 1967, The American journal of physiology.

[48]  J. Ross,et al.  CLINICAL OBSERVATIONS ON PAIRED ELECTRICAL STIMULATION OF THE HEART. EFFECTS ON VENTRICULAR PERFORMANCE AND HEART RATE. , 1964, The American journal of medicine.

[49]  E. Sonnenblick,et al.  Force-velocity relations in mammalian heart muscle. , 1962, The American journal of physiology.